{"title":"Immune Globulin Injection Syringes","description":"\u003cp\u003eShop our \u003cstrong\u003eImmune Globulin Injection Syringes\u003c\/strong\u003e—trusted for immune support, infection prevention, and rapid antibody therapy. Specially designed for safe, accurate dosing in immunodeficiency, autoimmune disorders, and urgent viral protection, these syringes ensure patient safety and enhanced immunity. FDA-approved, sterile, and latex-free, our Immune Globulin Injection Syringes are perfect for hospitals, clinics, and home care. Order now for fast shipping and reliable health protection.\u003c\/p\u003e","products":[{"product_id":"hyperrho-s-d-immune-globulin-whs-250u-250-mcg-prefilled-syringes-10-box","title":"Rho (D) Immune Globulin (Human) HyperRHO S\/D Mini-Dose 250 IU (50 MCG) Prefilled Syringes 10\/Box (Rx)","description":"HyperRHO® S\/D Mini-Dose (RhO[D] immune globulin [human]) is recommended to prevent the isoimmunization of RhO(D)-negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation provided the following criteria are met: The mother must be RhO(D) negative and must not already be sensitized to the RhO(D) antigen. The father is not known to be RhO(D) negative. Gestation is not more than 12 weeks at termination.\n\u003cp\u003eHyperRHO S\/D is an immune globulin with a high level of preformed antibodies against rhesus (Rh)-positive blood cells.\u003cbr\u003eThe injection of an RHO(D) immune globulin provides a passive immunity for rapid immune protection and an acute response in high-risk situations.\u003cbr\u003eHyperRHO S\/D destroys any Rh-positive blood cells that may have entered the mother's bloodstream and prevents the mother's immune system from producing Rh-positive antibodies, thus protecting the baby from developing hemolytic disease.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eEach single-dose syringe of HyperRHO S\/D contains sufficient anti-RhO(D) to effectively suppress the immunizing potential of 15 mL of Rh-positive red blood cells.\u003cbr\u003e\u003cbr\u003eAntepartum and postpartum administration of a single dose of HyperRHO S\/D to susceptible Rh-negative women reduces the incidence of Rh isoimmunization to less than 0.1%.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eEffective Protection\u003c\/strong\u003e\u003cbr\u003eHyperRHO S\/D destroys Rh-positive cells in the mother's body, prevents the mother's immune system from producing Rh-positive antibodies, and protects the baby from contracting HDN.\u003cbr\u003e\u003c\/p\u003e","brand":"Grifols Therapeutics","offers":[{"title":"Default Title","offer_id":39924081033288,"sku":"13533-0661-06","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Rho-_D_-Immune-Globulin-_Human_-HyperRHO-by-Grifols-Therapeutics.jpg?v=1725625340"},{"product_id":"hyperrho-s-d-whs-immune-globulin-full-dose-300u-300-mcg-prefilled-syringes-1-box","title":"HyperRHO S\/D WHS, Immune Globulin Full-Dose  300U (300 MCG) Prefilled Syringe 1\/Box (Rx) *Refrigerated*","description":"\u003cp\u003eHyperRHO® S\/D Full Dose (RhO[D] immune globulin [human]) is indicated for the prevention of Rh HDN and the prevention of isoimmunization in RhO(D)-negative individuals who have been transfused with RhO(D)-positive red blood cells.\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e* Refrigerated Item, Ships Next Day Air, SIGNATURE REQUIRED *\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eHyperRHO S\/D is an immune globulin with a high level of preformed antibodies against rhesus (Rh)-positive blood cells.\u003cbr\u003eThe injection of an RHO(D) immune globulin provides a passive immunity for rapid immune protection and an acute response in high-risk situations.\u003cbr\u003eHyperRHO S\/D destroys any Rh-positive blood cells that may have entered the mother's bloodstream and prevents the mother's immune system from producing Rh-positive antibodies, thus protecting the baby from developing hemolytic disease.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eEach single-dose syringe of HyperRHO S\/D contains sufficient anti-RhO(D) to effectively suppress the immunizing potential of 15 mL of Rh-positive red blood cells.\u003cbr\u003e\u003cbr\u003eAntepartum and postpartum administration of a single dose of HyperRHO S\/D to susceptible Rh-negative women reduces the incidence of Rh isoimmunization to less than 0.1%.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eEffective Protection\u003c\/strong\u003e\u003cbr\u003eHyperRHO S\/D destroys Rh-positive cells in the mother's body, prevents the mother's immune system from producing Rh-positive antibodies, and protects the baby from contracting HDN.\u003cbr\u003e\u003c\/p\u003e","brand":"Grifols Therapeutics","offers":[{"title":"Default Title","offer_id":39924081590344,"sku":"13533-0631-02","price":189.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/RHO-Immune-Globulin-_Human_-300-mcg-by-Grifols-13533-0631-02.jpg?v=1724353748"},{"product_id":"panzyga-10-2500-mg-immune-globulin-subcutaneous-human-ifas-10-solution-25-ml","title":"Panzyga 10% (2500 mg) (Immune Globulin Subcutaneous (Human)-ifas, 10% Solution) 25 mL","description":"\u003cp\u003ePanzyga 10% (2500 mg) is an intravenous immune globulin therapy used to manage immune deficiencies and autoimmune conditions. It is primarily prescribed for primary immunodeficiency (PI), where it provides essential antibodies to enhance the immune response and prevent infections. Additionally, Panzyga is used for treating chronic inflammatory demyelinating polyneuropathy (CIDP), helping to improve muscle strength and mobility by modulating immune system activity. The treatment is pivotal in supporting patients with compromised immune functions and reducing the frequency and severity of infections.\u003c\/p\u003e\n\u003cp\u003ePanzyga 10% (2500 mg) Immune Globulin Subcutaneous (Human) is used for the treatment of primary immunodeficiency (PI), boosting the immune system by providing necessary antibodies. It is also effective for chronic inflammatory demyelinating polyneuropathy (CIDP), helping to alleviate symptoms and improve muscle strength. Panzyga works by replacing or supplementing antibodies in patients with antibody deficiencies, thus offering protection against infections and supporting immune system function..\u003c\/p\u003e\n\u003cp\u003ePanzyga 10% is a premium intravenous immunoglobulin (IVIG) therapy proudly presented by Octapharma. Intended for patients with compromised immune systems, Panzyga 10% provides critical passive immunity that helps to fight against infections. This innovative treatment comes in a 25 mL vial containing 2500 mg of purified immune globulin for subcutaneous or intravenous administration. Sourced from healthy human plasma, Panzyga 10% conforms to impeccable standards of safety and effectiveness, fortifying patients’ immune defense with unmatched reliability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProduct Details and Features\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eConcentration:\u003c\/strong\u003e 10% Immunoglobulin G (IgG) solution\u003cbr\u003e\u003cstrong\u003eDosage Form: \u003c\/strong\u003e2500 mg in 25 mL (equivalent to 10% solution)\u003cbr\u003e\u003cstrong\u003eAdministration:\u003c\/strong\u003e Intravenous (IV) or Subcutaneous (SC)\u003cbr\u003e\u003cstrong\u003eSource: \u003c\/strong\u003eHuman plasma\u003cbr\u003e\u003cstrong\u003ePurity: \u003c\/strong\u003eMaximum removal of IgA, less than 50 mcg\/mL\u003cbr\u003e\u003cstrong\u003eManufacturer:\u003c\/strong\u003e Octapharma, a leader in plasma derivatives\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePanzyga functions by delivering a high concentration of Immunoglobulin G (IgG) antibodies, collected from the plasma of healthy donors, directly into the patient's circulation. These antibodies are broad-spectrum in their ability to neutralize pathogens such as bacteria and viruses, as well as modulating the immune response, providing its therapeutic effect in a variety of conditions like primary immunodeficiencies and autoimmune disorders. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDirections for Use\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1. Administration:\u003c\/strong\u003e Panzyga 10% can be administered intravenously or subcutaneously, depending on the indication and patient need. \u003cbr\u003e\u003cstrong\u003e2. Dosing:\u003c\/strong\u003e Dosage should be individualized based on patient condition, weight, and clinical response. \u003cbr\u003e\u003cstrong\u003e3. Preparation:\u003c\/strong\u003e Visually inspect for particulate matter and discoloration. Do not shake.\u003cbr\u003e\u003cstrong\u003e4. Infusion Rate:\u003c\/strong\u003e Begin at a slow rate with a gradual increase contingent upon patient tolerance.\u003c\/p\u003e\n\u003cp\u003eConsult healthcare professional guidelines for precise administration protocol.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Be aware of potential allergic reactions; contraindicated in individuals with known hypersensitivity to immunoglobulin preparations.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBlood Glucose Monitoring:\u003c\/strong\u003e This product may affect measurements; specifically use monitoring systems PCA or PDMS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRenal Dysfunction:\u003c\/strong\u003e Monitor renal function; cases of renal failure have been reported.\u003cbr\u003e\u003cstrong\u003e\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThrombosis:\u003c\/strong\u003e Exercise caution for individuals with a history of thrombosis. Ensure adequate hydration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eSide Effects\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eCommon side effects may include:\u003c\/em\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMild to moderate headache\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eFatigue and fever\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eInfusion site reactions like redness or swelling\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eNausea\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eHypertension\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRare but serious reactions might include:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnaphylaxis\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eThromboembolic events\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eHemolytic anemia\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcute renal failure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e Disclaimer\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis information serves as a summary of the essential aspects regarding the administration and potential impact of Panzyga 10%. Comprehensive prescribing information, direction from healthcare professionals, and personalized patient assessments are necessary to optimize the safe and effective use of Panzyga 10%.\u003c\/p\u003e","brand":"Octapharma USA","offers":[{"title":"Default Title","offer_id":51678771347824,"sku":"68982-0822-02","price":799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Panzyga-10_-by-Pfizer.jpg?v=1731594400"},{"product_id":"sodium-phenylacetate-and-benzoate-injection-20-ml-single-dose-vial-rx","title":"Sodium Phenylacetate and Benzoate Injection 20 mL Single-Dose Vial (RX)","description":"\u003cp\u003eSodium Phenylacetate and Sodium Benzoate Injection is an advanced therapeutic solution designed for the acute management of urea cycle disorders (UCDs) in patients experiencing hyperammonemia. This combination injection provides critical care support by facilitating the detoxification and excretion of ammonia, which is crucial for patients unable to naturally eliminate waste nitrogen due to genetic urea cycle deficiencies. Its rapid action and proven effectiveness make it an essential choice in critical care settings, helping stabilize patient conditions and prevent the deleterious effects of elevated blood ammonia levels.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProduct Details and Features:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eComposition:\u003c\/strong\u003e Each 20 mL single-dose vial contains an equimolar combination of sodium phenylacetate and sodium benzoate. \u003cbr\u003e\u003cstrong\u003eConcentration:\u003c\/strong\u003e Optimized molecular pairing for effective ammonia scavenging.\u003cbr\u003e\u003cstrong\u003eFormat:\u003c\/strong\u003e Supplied as a sterile, clear solution that can be easily prepared and administered intravenously.\u003cbr\u003e\u003cstrong\u003eQuality Assurance: \u003c\/strong\u003eManufactured by Zydus Pharmaceuticals, ensuring adherence to rigorous quality control standards.\u003cbr\u003e\u003cstrong\u003eIndication:\u003c\/strong\u003e Primarily utilized in hospitals for the management of acute hyperammonemia episodes associated with UCDs, including deficits in carbamoyl phosphate synthetase, ornithine transcarbamylase, and argininosuccinate synthetase.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium phenylacetate and sodium benzoate serve as ammonia scavengers. Sodium phenylacetate works by converting to phenylacetylglutamine through conjugation with glutamine, which is then excreted through the kidneys. Phenylacetylglutamine is structurally similar to urea and aids in the excretion of excess nitrogen. Sodium benzoate, on the other hand, conjugates with glycine to form hippurate, which is also excreted in urine, further assisting in the removal of ammonia from the bloodstream. This dual action efficiently lowers ammonia levels, providing a vital therapeutic benefit in hyperammonemic emergencies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDirections for Use:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdministration:\u003c\/strong\u003e Administer intravenously under the supervision of a healthcare professional.\u003cbr\u003e\u003cstrong\u003eDosage:\u003c\/strong\u003e The typical starting dose is patient-specific and based on body weight and clinical condition; initiate treatment as promptly as possible in hyperammonemic crises.\u003cbr\u003e\u003cstrong\u003ePreparation:\u003c\/strong\u003e Dilute to appropriate volume according to medical guidance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWarnings:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eContraindications:\u003c\/strong\u003e Known hypersensitivity to sodium phenylacetate, sodium benzoate, or any formulation components.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePrecautions: \u003c\/strong\u003eCaution in patients with heart failure, renal impairment, or fluid retention concerns. Continually monitor essential biochemical parameters.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy and Lactation: \u003c\/strong\u003eShould be administered to pregnant or nursing mothers only if clearly needed and under strict medical guidance.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitive Reactions: \u003c\/strong\u003eWatch for any signs of allergic reactions, particularly in patients with common sensitivities to ingredients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eSide Effects:\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eWhile generally well-tolerated under medical supervision, potential side effects include:\u003c\/em\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic Acidosis:\u003c\/strong\u003e Monitor changes in acid-base balance.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFluid and Electrolyte Disturbances:\u003c\/strong\u003e Possible due to sodium content.\u003cbr\u003e\u003cstrong\u003e\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInjection Site Reaction:\u003c\/strong\u003e Includes pain, redness, or swelling at infusion site.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGastrointestinal Discomfort:\u003c\/strong\u003e Possible nausea, vomiting, or aversion reactions.\u003cbr\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeurological Effects:\u003c\/strong\u003e Dizziness or headache in rare cases; necessitates regular monitoring.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn the event of adverse reactions, adjust the dosage or discontinue use according to clinical assessments. Ensure ongoing patient monitoring throughout and beyond treatment periods for optimal recovery and stable metabolic conditions. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This information is intended for healthcare professionals familiar with patient prescription formulations and hyperammonemia management. Please consult the official product insert and medical guidelines for comprehensive details and updates specific to clinical environments.\u003c\/p\u003e","brand":"Zydus Pharmaceutical","offers":[{"title":"Default Title","offer_id":51796451361136,"sku":"70710-1926-01","price":3400.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Sodium-Phenylacetate-and-Benzoate-Injection.jpg?v=1737561266"},{"product_id":"hyperrab-rabies-vaccine-immune-globulin-injection-rapid-rabies-protection","title":"HyperRAB Rabies Vaccine Immune Globulin Injection Dosage Vial 1 mL (300 Units) (RX)","description":"\u003cp\u003eHyperRAB Rabies vaccine Immune Globulin Injection is a sterile solution containing human antibodies specifically targeted against the rabies virus. It is used as part of post-exposure prophylaxis for individuals who have potentially been exposed to rabies, such as through an animal bite or scratch, and who have not previously been vaccinated against rabies. HyperRAB Rabies vaccine provides immediate, but temporary, passive immunity by supplying ready-made antibodies that help neutralize the virus until the person’s own immune system can respond to the rabies vaccine, which is administered at the same time. The medication is given by infiltrating as much of the dose as possible into and around the wound, while any remaining amount is injected into a muscle away from the site where the rabies vaccine is given. HyperRAB Rabies vaccine is used only once at the beginning of rabies post-exposure treatment and should always be combined with a rabies vaccine for full protection. Common side effects may include soreness at the injection site, mild fever, or headache, while serious allergic reactions are rare.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"block _00hoS\"\u003e\u003cstrong\u003eHyperRAB\u003c\/strong\u003e is a high-potency rabies immune globulin (Human) formulated for immediate, short-term passive immunization against the rabies virus following suspected exposure. This solution contains 300 International Units (IU) per 1 mL, designed for precise and effective administration in rabies post-exposure prophylaxis (PEP).\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eWhat It Is Used For\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHyperRAB\u003c\/strong\u003e is indicated for individuals who have been exposed, or potentially exposed, to rabies virus, typically via bites, scratches, or mucosal contact from a potentially rabid animal. It is always administered in conjunction with rabies vaccine as part of the recommended rabies PEP regimen.\u003c\/p\u003e\n\u003ch3\u003eImportant: CDC Guidelines for Use\u003c\/h3\u003e\n\u003cp\u003eAccording to the \u003cstrong\u003eCenters for Disease Control and Prevention (CDC)\u003c\/strong\u003e guidelines:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRabies Immune Globulin (RIG)\u003c\/strong\u003e must be used in conjunction with rabies vaccine for previously unvaccinated individuals.\u003c\/li\u003e\n\u003cli\u003eRIG should be infiltrated around and into the wound site as soon as possible after exposure, followed by the rabies vaccine series.\u003c\/li\u003e\n\u003cli\u003eRIG should not be administered to persons who have been previously vaccinated against rabies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eDosage and Administration\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStandard Dose:\u003c\/strong\u003e 20 IU\/kg body weight (infiltrate as much as possible into and around the wound; any remaining should be injected intramuscularly at a site distant from vaccine administration).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePreparation:\u003c\/strong\u003e Each vial contains 1 mL of solution (300 IU\/mL).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRoute:\u003c\/strong\u003e Infiltration into wound(s) and\/or intramuscular injection.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFrequency:\u003c\/strong\u003e Single administration at initiation of rabies PEP, \u003cstrong\u003enever after day 7\u003c\/strong\u003e of starting rabies vaccine, as it may interfere with the active immune response.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eDirections\u003c\/h4\u003e\n\u003col\u003e\n\u003cli\u003e\u003cstrong\u003eInitiate therapy immediately after exposure.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCalculate total volume required based on patient weight (20 IU\/kg).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSlowly infiltrate as much of the total dose as anatomically feasible around the wound(s).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAdminister the remainder intramuscularly, distant from the rabies vaccine injection site.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch3\u003eMechanism of Action\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHyperRAB\u003c\/strong\u003e contains concentrated antibodies (IgG) specifically active against the rabies virus. It provides immediate passive immunity by neutralizing the virus at the wound site and in tissues before the patient’s own immune response develops following vaccination.\u003c\/p\u003e\n\u003ch3\u003eProduct Details and Features\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNDC:\u003c\/strong\u003e 13533-0318-01\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturer:\u003c\/strong\u003e Grifols Therapeutics\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSterile, preservative-free, single-use vial\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh concentration (300 IU\/mL) for efficient administration\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReady-to-use liquid formulation\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGamma globulin fraction of human plasma\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMaximum safety via donor screening, viral inactivation, and purification steps\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWarnings and Precautions\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Contraindicated in persons with known history of anaphylactic or severe systemic reaction to human immunoglobulin preparations.\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDo NOT inject intravenously.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003eUse with caution in individuals with IgA deficiency.\u003c\/li\u003e\n\u003cli\u003eRisk of transmitting infectious agents, including viruses and theoretically prions, cannot be completely eliminated due to human plasma source.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDo not exceed the recommended dose\u003c\/strong\u003e—excessive immunoglobulin can interfere with the efficacy of active rabies vaccination.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSide Effects\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eCommon Adverse Reactions:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLocal reactions (pain, tenderness, erythema, bruising at injection site)\u003c\/li\u003e\n\u003cli\u003eSystemic symptoms (headache, malaise, low-grade fever, chills)\u003c\/li\u003e\n\u003cli\u003eAllergic reactions (urticaria, rash, rarely anaphylaxis)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eReport any severe or unusual reactions to your healthcare provider immediately.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eStore at 2–8°C (36–46°F). Do not freeze. Protect from light.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan class=\"block _00hoS\"\u003e\u003cstrong\u003eHyperRAB 1 mL (300 IU\/mL) by Grifols Therapeutics\u003c\/strong\u003e is your trusted solution for immediate immune protection following potential rabies exposure, fully compliant with CDC rabies post-exposure guidelines. Ensure proper administration for optimal results and minimized risk. Always consult your healthcare professional for individualized PEP regimens.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"block _00hoS\"\u003e\u003cstrong\u003eOrder HyperRAB today for reliable, fast-acting rabies post-exposure prophylaxis!\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"Grifols Therapeutics","offers":[{"title":"Default Title","offer_id":52279651860848,"sku":"13533-0318-01","price":999.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/HyperRAB--human-rabies-immune-globulin.jpg?v=1747657318"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/collections\/Immune-Globulin-Injection-Syringes.jpg?v=1718649159","url":"https:\/\/www.mountainside-medical.com\/collections\/immune-globulin\/human-immune-globulin+immunoglobulin.oembed","provider":"Mountainside Medical","version":"1.0","type":"link"}